1029 related articles for article (PubMed ID: 19467365)
1. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
2. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
3. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N
J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965
[TBL] [Abstract][Full Text] [Related]
6. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response.
Rosen RH; Gupta AK; Tyring SK
J Am Acad Dermatol; 2012 Mar; 66(3):486-93. PubMed ID: 22055282
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
[TBL] [Abstract][Full Text] [Related]
8. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT.
Berman B; Nestor MS; Newburger J; Park H; Swenson N
J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702
[TBL] [Abstract][Full Text] [Related]
9. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
Bettencourt MS
J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
[TBL] [Abstract][Full Text] [Related]
10. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
Keating GM
Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
[TBL] [Abstract][Full Text] [Related]
11. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.
Augustin M; Tu JH; Knudsen KM; Erntoft S; Larsson T; Hanke CW
J Am Acad Dermatol; 2015 May; 72(5):816-21. PubMed ID: 25770879
[TBL] [Abstract][Full Text] [Related]
12. Ingenol mebutate: a new option for actinic keratosis treatment.
Gras J
Drugs Today (Barc); 2013 Jan; 49(1):15-22. PubMed ID: 23362492
[TBL] [Abstract][Full Text] [Related]
13. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial.
Jorizzo J; Weiss J; Furst K; VandePol C; Levy SF
Arch Dermatol; 2004 Jul; 140(7):813-6. PubMed ID: 15262691
[TBL] [Abstract][Full Text] [Related]
14. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).
Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F
Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study.
Garbe C; Basset-Seguin N; Poulin Y; Larsson T; Østerdal ML; Venkata R; Lear JT
Br J Dermatol; 2016 Mar; 174(3):505-13. PubMed ID: 26471889
[TBL] [Abstract][Full Text] [Related]
16. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses.
Ulrich C; Johannsen A; Röwert-Huber J; Ulrich M; Sterry W; Stockfleth E
Eur J Dermatol; 2010; 20(4):482-8. PubMed ID: 20507841
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
18. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
[TBL] [Abstract][Full Text] [Related]
19. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
20. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
